足癬治療市場 - 藥物類別、疾病類型、給藥途徑、類型、年齡層、配銷通路、全球預測

由於治療方法的快速進步和 RampD 投資的增加，全球足癬治療市場在 2024 年至 2032 年間的複合年成長率將達到 4.3%。微針貼片等創新療法為傳統抗真菌藥物提供了有效且便利的替代方案，可改善患者的治療效果。

RampD 投資的增加也推動了新型藥物輸送系統和更有效治療方法的發現，以應對不斷上升的真菌感染發病率。這些進步正在提高治療效果、患者依從性和市場可近性，進一步促進市場擴張。例如，2023年7月，香港大學李嘉誠醫學院臨床醫學院骨科及創傷學系的Kelvin Yeung領導的研究團隊開發了一種新的微針貼片，為患者提供有效的非抗生素治療治療皮膚感染，包括足癬。

該行業分為藥物類別、疾病類型、給藥途徑、類型、年齡層、配銷通路和地區。

從給藥途徑來看，由於處方藥的功效和可靠性，到 2032 年，處方藥領域的足癬治療市場將顯著擴張。與非處方藥相比，這些治療方法通常含有更高濃度的活性成分，可以更有效、更快速地緩解症狀。醫療保健專業人士也經常建議持續或嚴重病例的處方治療。

根據配銷通路，零售藥房領域的足癬治療行業將在 2032 年獲得可觀的收益，這要歸功於其廣泛的可及性和便利性，為尋求非處方藥和處方藥的消費者提供便利。零售藥局提供多種治療選擇，從外用藥膏到口服抗真菌藥，使患者可以輕鬆獲得必要的治療。隨著醫療保健意識和對有效治療的需求不斷成長，對零售藥局的偏好將進一步上升。

在人口快速成長、真菌感染發病率增加以及足部衛生意識不斷提高的推動下，亞太地區足癬治療市場從 2024 年到 2032 年將出現顯著的複合年成長率。該地區不斷擴大的醫療基礎設施和更高的可支配收入使人們能夠更多地獲得非處方藥和處方藥治療。此外，主要市場參與者的存在和治療方案的持續進步將有助於區域產業的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 足癬盛行率增加
    • 有效非處方藥的可用性
    • 人們對足癬及其症狀的認知不斷提高
  • 產業陷阱與挑戰
    • 抗真菌藥物抗藥性增加
    • 替代治療方案的可用性
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 抗黴菌藥
• 組合藥物

第 6 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 指間足癬
• 足底足癬
• 水泡性足癬
• 急性潰瘍性足癬

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
  • 專題
  • 奶油
  • 凝膠
  • 洗劑
  • 粉末
  • 噴
  • 口服

第 8 章：市場估計與預測：按類型 2021 - 2032

• 主要趨勢
• 非處方藥
• 處方藥

第 9 章：市場估計與預測：按年齡分類，2021 - 2032

• 主要趨勢
• 18歲以下
• 19 - 35 歲
• 36 - 50 歲
• 51歲以上

第 10 章：市場估計與預測：按配銷通路，2021 - 2032

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 12 章：公司簡介

• Bausch Health Companies Inc.
• Bayer AG
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• Pfizer, Inc.
• Sebela Pharmaceuticals Holdings Inc.
• Smith & Nephew plc
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Limited
• Viatris Inc.

Global Tinea Pedis Treatment Market will register 4.3% CAGR between 2024 and 2032, owing to rapid advancements in treatment methods and increased R&D investments. Innovative therapies, such as microneedle patches, are providing effective and convenient alternatives to traditional antifungal medications for enhancing patient outcomes.

Increased R&D investments are also fuelling the discovery of novel drug delivery systems and more potent treatments for addressing the rising incidence of fungal infections. These advancements are improving treatment efficacy, patient compliance, and market accessibility, further contributing to the market expansion. For instance, in July 2023, a research team headed by Kelvin Yeung from the Department of Orthopaedics and Traumatology at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong HKUMed developed a new microneedle patch for offering an effective non-antibiotic treatment for skin infections, including tinea pedis.

The industry is segmented into drug class, disease type, route of administration, type, age group, distribution channel, and region.

By route of administration, the tinea pedis treatment market from the prescription segment will witness remarkable expansion through 2032 due to the efficacy and reliability of prescription medications. These treatments often contain higher concentrations of active ingredients compared to over-the-counter OTC options for providing more effective and faster relief from symptoms. Healthcare professionals also frequently recommend prescription treatments for persistent or severe cases.

Based on distribution channel, the tinea pedis treatment industry from the retail pharmacies segment will garner considerable gains by 2032, attributed to their widespread accessibility and convenience for consumers seeking OTC and prescription medications. Retail pharmacies provide a variety of treatment options, from topical creams to oral antifungals, making it easy for patients to obtain necessary treatments. As healthcare awareness and the demand for effective treatments is growing, the preference for retail pharmacies will further rise.

Asia Pacific tinea pedis treatment market will witness a noteworthy CAGR from 2024 to 2032, propelled by the rapidly growing population, increasing incidence of fungal infections, and rising awareness about foot hygiene. The expanding healthcare infrastructure and higher disposable incomes of the region are enabling greater access to both OTC and prescription treatments. Additionally, the presence of major market players and ongoing advancements in treatment options will contribute to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of tinea pedis
    • 3.2.1.2 Availability of effective OTC drugs
    • 3.2.1.3 Growing awareness about tinea pedis and its symptoms
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Increased resistance to antifungal medications
    • 3.2.2.2 Availability of alternative treatment options
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antifungals
• 5.3 Combination drugs

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Interdigital tinea pedis
• 6.3 Plantar tinea pedis
• 6.4 Vesicular tinea pedis
• 6.5 Acute ulcerative tinea pedis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
  • 7.1.1 Topical
  • 7.1.2 Cream
  • 7.1.3 Gel
  • 7.1.4 Lotion
  • 7.1.5 Powder
  • 7.1.6 Spray
  • 7.1.2 Oral

Chapter 8 Market Estimates and Forecast, By Type 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 OTC drugs
• 8.3 Prescription drugs

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Below 18 years
• 9.3 19 - 35 years
• 9.4 36 - 50 years
• 9.5 51 years and above

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Bausch Health Companies Inc.
• 12.2 Bayer AG
• 12.3 GlaxoSmithKline plc
• 12.4 Glenmark Pharmaceuticals Limited
• 12.5 Pfizer, Inc.
• 12.6 Sebela Pharmaceuticals Holdings Inc.
• 12.7 Smith & Nephew plc
• 12.8 Sun Pharmaceutical Industries Ltd
• 12.9 Teva Pharmaceutical Industries Limited
• 12.10 Viatris Inc.